Viewing Study NCT05171660

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:08 AM
Ignite Modification Date: 2026-02-24 @ 11:01 AM
Study NCT ID: NCT05171660
Status: RECRUITING
Last Update Posted: 2025-06-15
First Post: 2021-11-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Colorectal Cancer Stage IV View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Colorectal Cancer Stage IV, View
None RAS gene mutation View
None Microsatellite stable View